afatinib dimaleate
Marketedupdated 2mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
nothing on the calendar yet
no news has mentioned this drug yet
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
comments(0)
5-min edit window · permanent after that